Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock
Berenberg sees potential upside to Lilly’s full-year 2026 revenue forecast, which ranges from $85 billion to $87 billion. Lilly to present latest data from the Phase 3 Triumph-2 results for Retatrutide, its investigational obesity drug. Lilly will also present results from the Achieve-4 trial, its largest diabetes study of oral GLP-1 Foundayo. Berenberg upgraded Lilly … Read more